SCM
LUCD icon

Sterling Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Sterling Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559 Sell
522
-1,378
-73% -$1.49K ﹤0.01% 3215
2026
Q1 		$2.19K Sell
1,900
-1,096
-37% -$1.4K ﹤0.01% 2975
2025
Q4 		$3.27K Buy
2,996
+124
+4% +$139 ﹤0.01% 2993
2025
Q3 		$2.9K Buy
2,872
+1,734
+152% +$1.89K ﹤0.01% 2919
2025
Q2 		$1.31K Buy
+1,138
New +$1.47K ﹤0.01% 3017

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Sterling Capital Management's LUCD Position: Q2 2026 in Review

Sterling Capital Management reduced its Lucid Diagnostics (LUCD) stake by 73% in Q2 2026, selling an estimated $1.49K and leaving 522 shares worth $559. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

Sterling Capital Management first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.27K in Q4 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Sterling Capital Management held 522 shares of Lucid Diagnostics worth $559 as of Q2 2026.
  • Sterling Capital Management sold 1,378 Lucid Diagnostics shares in Q2 2026, an estimated $1.49K.
  • Lucid Diagnostics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3215 holding.
  • Sterling Capital Management first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Lucid Diagnostics position peaked at $3.27K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.